These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9562136)

  • 1. Pemoline therapy resulting in liver transplantation.
    Adcock KG; MacElroy DE; Wolford ET; Farrington EA
    Ann Pharmacother; 1998 Apr; 32(4):422-5. PubMed ID: 9562136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemoline hepatotoxicity in children.
    Marotta PJ; Roberts EA
    J Pediatr; 1998 May; 132(5):894-7. PubMed ID: 9602211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemoline in ADHD.
    Winsberg B; Barbato M
    J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321
    [No Abstract]   [Full Text] [Related]  

  • 4. Pemoline (Cylert): market withdrawal.
    Hogan V
    CMAJ; 2000 Jan; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract]   [Full Text] [Related]  

  • 5. Pemoline-associated fulminant liver failure: testing the evidence for causation.
    Berkovitch M; Pope E; Phillips J; Koren G
    Clin Pharmacol Ther; 1995 Jun; 57(6):696-8. PubMed ID: 7781270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial.
    Bostic JQ; Biederman J; Spencer TJ; Wilens TE; Prince JB; Monuteaux MC; Sienna M; Polisner DA; Hatch M
    J Child Adolesc Psychopharmacol; 2000; 10(3):205-16. PubMed ID: 11052410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Biederman J; Spencer TJ; Frazier J; Prince J; Bostic J; Rater M; Soriano J; Hatch M; Sienna M; Millstein RB; Abrantes A
    J Clin Psychopharmacol; 1999 Jun; 19(3):257-64. PubMed ID: 10350032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemoline-associated hepatic failure: a critical analysis of the literature.
    Shevell M; Schreiber R
    Pediatr Neurol; 1997 Jan; 16(1):14-6. PubMed ID: 9044395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of compliance with FDA recommendations for pemoline (Cylert).
    Willy ME; Manda B; Shatin D; Drinkard CR; Graham DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):785-90. PubMed ID: 12108802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis.
    Rosh JR; Dellert SF; Narkewicz M; Birnbaum A; Whitington G
    Pediatrics; 1998 May; 101(5):921-3. PubMed ID: 9565425
    [No Abstract]   [Full Text] [Related]  

  • 12. A rare case of dependence on pemoline.
    Bonnet U; Davids E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1340-1. PubMed ID: 16600453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
    Rao JK; Julius JR; Breen TJ; Blethen SL
    Pediatrics; 1998 Aug; 102(2 Pt 3):497-500. PubMed ID: 9685452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 15. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.
    Riggs PD; Thompson LL; Mikulich SK; Whitmore EA; Crowley TJ
    J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse.
    Heiligenstein E; Anders J
    J Am Coll Health; 1997 Mar; 45(5):225-9. PubMed ID: 9069682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A surveillance method for the early identification of idiosyncratic adverse drug reactions.
    Etwel FA; Rieder MJ; Bend JR; Koren G
    Drug Saf; 2008; 31(2):169-80. PubMed ID: 18217792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study.
    Heiligenstein E; Johnston HF; Nielsen JK
    J Am Coll Health; 1996 Jul; 45(1):35-9. PubMed ID: 8708264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of autoimmune hepatitis: another hepatotoxic effect of pemoline therapy.
    Hochman JA; Woodard SA; Cohen MB
    Pediatrics; 1998 Jan; 101(1 Pt 1):106-8. PubMed ID: 9417161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.